Carisma Therapeutics to Feature CEO in Upcoming Health Conference
PHILADELPHIA, Nov. 27, 2024 /PRNewswire/ — Carisma Therapeutics Inc. CARM (“Carisma” or the “Company”), a clinical-stage biopharmaceutical firm dedicated to advancing innovative immunotherapies, will have President and Chief Executive Officer, Steven Kelly, participate in a fireside chat during the 7th Annual Evercore ISI HealthCONx Conference on Thursday, December 5th at 9:35 am ET.
An audio webcast of this event can be found in the Company’s Investor Events section on their Investor Relations webpage. It will be available for a limited time post-event.
About Carisma
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company that uses its unique macrophage and monocyte cell engineering platform to create groundbreaking immunotherapies for cancer and other serious ailments. By focusing on engineered macrophages and monocytes, which are vital to the body’s immune system, Carisma aims to develop innovative solutions. The Company is based in Philadelphia, PA. To learn more, visit www.carismatx.com.
Investors:
Shveta Dighe
Head of Investor Relations
investors@carismatx.com
Media Contact:
Julia Stern
(763) 350-5223
jstern@realchemistry.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/carisma-therapeutics-to-participate-in-the-7th-annual-evercore-isi-healthconx-conference-302316979.html
SOURCE Carisma Therapeutics Inc.
Market News and Data brought to you by Benzinga APIs
